Widespread use of lifesaving artificial blood could be a reality by the end of the decade, according to published reports.
Clinical trials are underway at Nara Medical University in Japan after researchers administered a prototype to a small group of volunteers earlier this year with no significant side effects.
The product contains hemoglobin molecules from expired donor blood, which are encapsulated in protective lipid shells to create artificial red blood cells. As with regular blood, the new mixture is capable of carrying oxygen throughout the body.
Unlike blood from humans, however, the artificial variety being tested in Japan does not need to match a certain blood type for transfusions. Like “universal donor” Type O- blood, the manufactured blood is considered usable for any blood type.
What’s more, artificial blood is reportedly storable for up to two years — far longer than organic blood, which cannot be used after 42 days.
Artificial blood is considered a solution to chronic blood bank shortages, which can be especially life-threatening in underdeveloped parts of the world.
Nara Medical University reportedly aims to roll out its artificial blood in 2030, pending the success of its clinical trials.
